Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Down 17.7 %

Shares of NASDAQ:BCLI opened at $0.91 on Friday. Brainstorm Cell Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $10.05. The company has a market cap of $5.96 million, a PE ratio of -0.19 and a beta of 0.60. The company’s 50-day moving average price is $1.52 and its 200 day moving average price is $1.82.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.